1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer : insights from the randomized SweBCG91RT trial
- Contribution to journal › Article
- 2017
-
Mark
Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular Reprogramming
- Contribution to journal › Article